Main Menu

Our Work

Bates White provides reasonable royalty damages estimate in Amgen biosimilar case

Bates White Partner Randal Heeb testified at a jury trial on behalf of Amgen in its recent patent infringement lawsuit against Pfizer subsidiary Hospira. On September 22, 2017, the jury found that Hospira owed Amgen $70 million in damages for manufacturing its biosimilar prior to the expiration of Amgen’s patents related to EPOGEN®, Amgen’s biological drug to treat patients with anemia. Dr. Heeb testified regarding the reasonable royalty that Hospira would have paid Amgen to manufacture its biosimilar, based on a model of the hypothetical negotiation between the parties. Additional coverage about the trial can be found here.

Jump to Page

We use cookies to optimize the performance of this site and give you the best user experience. By clicking "Accept," you agree to our use of cookies.

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytical Cookies

Analytical cookies help us improve our website by collecting and reporting information on its usage. We access and process information from these cookies at an aggregate level.